Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that GlaxoSmithKline's Coreg will be used more and more as a first line therapy as physicians become more comfortable with the drug. According to the new report entitled Treatment Algorithms in Chronic Heart Failure, 92% of primary care physicians and 86% of cardiologists identify better efficacy, particularly in patients with advanced chronic heart failure, as a reason for selecting Coreg over AstraZeneca's Toprol-XL.
"Our analysis of patient-level claims data reveals that 20% of Coreg prescriptions in CHF are for first-line treatment," said John Earl, Ph.D., principle director at Decision Resources. "However by 2009, primary care physicians and cardiologists expect that percentage to increase by almost 50%, with cardiologists anticipating that almost half of their Coreg prescriptions will be for first line."
The report also finds that ACE inhibitors are considered the cornerstone of chronic heart failure therapy for their ability to prolong survival. Lisinopril (AstraZeneca's Zestril/Merck's Prinivil, generics) is the most commonly used first-line ACE inhibitor among newly diagnosed chronic heart failure patients due to its availability in an inexpensive generic form, and because it is supported by data from the Assessment of Treatment with Lisinopril and Survival (ATLAS) trial, which showed significant reductions in mortality and hospitalization when Lisinopril is added to "standard" treatments such as diuretics and digoxin.
About Treatment Algorithm Insight Series
Decision Resources combines in-depth primary research with the most extensive claims-based longitudinal patient-level data from PharMetrics® to provide exceptional insight into physicians' prescribing trends and the factors that drive therapy product choice, from diagnosis through multiple courses of treatment, for a specific disease.
For each disease examined, Decision Resources' Treatment Algorithms Insight Series provides:
-- Summary of U.S. medical practice based on interviews with leading experts in the field. -- Qualitative diagnosis/referral/treatment algorithm for the United States. -- Drug usage by lines of therapy (1st, 2nd, 3rd line). -- Discussion of key freeform combinations by lines of therapy. -- Product share (class and specific compound level) within each line of therapy (1st, 2nd, 3rd line). -- Progression of therapy from key 1st line products. -- Pathway to key therapies from previous therapies. -- Qualitative analysis of 2-year forecast incorporating upcoming launches, changes in reimbursement, etc. About Decision Resources
Decision Resources, Inc., (www.DecisionResources.com) is a world leader in healthcare market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 email@example.com
SOURCE: Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,
Web site: http://www.decisionresources.com/